Extended Follow-Up of Robot-Assisted Partial Nephrectomy for Renal Hilar Tumor: A Prospective Multi-Institutional Study (ROBOHIT Trial).

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology Pub Date : 2025-05-19 DOI:10.1111/iju.70116

Jun Teishima, Ryoichi Shiroki, Toshio Takagi, Masatoshi Eto, Shuichi Morizane, Toshinari Yamasaki, Yasuo Kohjimoto, Fumiya Hongo, Takuya Tsujino, Kensuke Bekku, Nobuyuki Hinata, Atsushi Okada, Tetsuya Yoshida, Tsunenori Kondo, Naoki Kawamorita, Hayato Yamamoto, Shuji Isotani, Masaki Shimbo, Jun Nagayama, Kunihisa Yamaguchi, Hidefumi Kinoshita, Hideaki Miyake

{"title":"Extended Follow-Up of Robot-Assisted Partial Nephrectomy for Renal Hilar Tumor: A Prospective Multi-Institutional Study (ROBOHIT Trial).","authors":"Jun Teishima, Ryoichi Shiroki, Toshio Takagi, Masatoshi Eto, Shuichi Morizane, Toshinari Yamasaki, Yasuo Kohjimoto, Fumiya Hongo, Takuya Tsujino, Kensuke Bekku, Nobuyuki Hinata, Atsushi Okada, Tetsuya Yoshida, Tsunenori Kondo, Naoki Kawamorita, Hayato Yamamoto, Shuji Isotani, Masaki Shimbo, Jun Nagayama, Kunihisa Yamaguchi, Hidefumi Kinoshita, Hideaki Miyake","doi":"10.1111/iju.70116","DOIUrl":null,"url":null,"abstract":"Objectives: We aimed to evaluate the long-term oncological and functional outcomes after robot-assisted partial nephrectomy (RAPN) for renal hilar tumors.Methods: A total of 22 academic hospitals in Japan participated in a prospective, multicenter, single-arm, open-label trial with a 2-year enrollment period. After undergoing RAPN, 105 patients with clinical T1 renal hilar tumors were followed up for 5 years and evaluated. Recurrence-free survival, overall survival, and trends of renal function were set as oncological and functional outcomes.Results: Five-year overall survival and recurrence-free survival were 98.0% and 89.2%, respectively. Mean estimated glomerular filtration rates (eGFRs) were 69.031 mL/min preoperatively, and were 59.374, 58.334, 58.221, 56.975, and 59.602 mL/min at 1, 2, 3, 4, and 5 years after surgery, respectively. While eGFR was significantly lower than the preoperative one at all points (p < 0.001), eGFRs at 1 and 5 years after surgery did not differ significantly (p = 0.793).Conclusion: After long-term follow-up, RAPN for clinical T1 renal hilar tumors continues to provide functional and oncological outcomes equivalent to those in the perioperative period.Trial registration: The study protocol was registered in the Japan Registry of Clinical Trials (jRCT1052190005, UMIN000023968).","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/iju.70116","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: We aimed to evaluate the long-term oncological and functional outcomes after robot-assisted partial nephrectomy (RAPN) for renal hilar tumors.

Methods: A total of 22 academic hospitals in Japan participated in a prospective, multicenter, single-arm, open-label trial with a 2-year enrollment period. After undergoing RAPN, 105 patients with clinical T1 renal hilar tumors were followed up for 5 years and evaluated. Recurrence-free survival, overall survival, and trends of renal function were set as oncological and functional outcomes.

Results: Five-year overall survival and recurrence-free survival were 98.0% and 89.2%, respectively. Mean estimated glomerular filtration rates (eGFRs) were 69.031 mL/min preoperatively, and were 59.374, 58.334, 58.221, 56.975, and 59.602 mL/min at 1, 2, 3, 4, and 5 years after surgery, respectively. While eGFR was significantly lower than the preoperative one at all points (p < 0.001), eGFRs at 1 and 5 years after surgery did not differ significantly (p = 0.793).

Conclusion: After long-term follow-up, RAPN for clinical T1 renal hilar tumors continues to provide functional and oncological outcomes equivalent to those in the perioperative period.

Trial registration: The study protocol was registered in the Japan Registry of Clinical Trials (jRCT1052190005, UMIN000023968).

查看原文本刊更多论文

机器人辅助部分肾切除术治疗肾门部肿瘤的延长随访：一项前瞻性多机构研究（ROBOHIT试验）。

目的：我们旨在评估机器人辅助部分肾切除术（RAPN）治疗肾门部肿瘤后的长期肿瘤和功能结果。方法：日本共有22家学术医院参与了一项前瞻性、多中心、单臂、开放标签的试验，入组期为2年。对105例临床T1型肾门部肿瘤患者行RAPN术后5年随访并进行评价。无复发生存期、总生存期和肾功能趋势作为肿瘤和功能预后。结果：5年总生存率为98.0%，无复发生存率为89.2%。平均估计肾小球滤过率（egfr）术前为69.031 mL/min，术后1、2、3、4和5年分别为59.374、58.334、58.221、56.975和59.602 mL/min。结论：经长期随访，临床T1期肾门部肿瘤的RAPN继续提供与围手术期相当的功能和肿瘤预后。试验注册：研究方案已在日本临床试验注册中心注册（jRCT1052190005, UMIN000023968）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Urology 医学-泌尿学与肾脏学

CiteScore

4.70

自引率

11.50%

发文量

340

审稿时长

3 months

期刊介绍： International Journal of Urology is the official English language journal of the Japanese Urological Association, publishing articles of scientific excellence in urology. Submissions of papers from all countries are considered for publication. All manuscripts are subject to peer review and are judged on the basis of their contribution of original data and ideas or interpretation.